3-tert-Butyl-6-isopropylpyridazin | 41398-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-tert-Butyl-6-isopropylpyridazin
• 英文别名: 3-tert-butyl-6-isopropyl-pyridazine；3-Tert-butyl-6-propan-2-ylpyridazine
• CAS: 41398-17-8
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.277
• InChiKey: LJYNEFZDPGQURG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210188845A1

  公开（公告）日：2021-06-24

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR 6 or N; Y is CR 3 or N; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了Formula (I)的化合物： 或其盐，其中：X为CR 6 或N；Y为CR 3 或N；R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 和m在此处定义。还揭示了使用这些化合物来抑制二酰甘油激酶α（DGKα）和二酰甘油激酶ζ（DGKζ）中的一个或两个活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面是有用的。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：giraFpharma LLC

  公开号：US20190106427A1

  公开（公告）日：2019-04-11

  Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Wee1抑制剂的杂环化合物。这些化合物可能被用作治疗剂，用于治疗疾病，并且可能在肿瘤学中发挥特定作用。
• NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF
  申请人：ACCUTAR BIOTECHNOLOGY INC.

  公开号：US20200157078A1

  公开（公告）日：2020-05-21

  The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

  本公开涉及具有雌激素受体α降解活性的新化合物，包含这些化合物的药物组合物，以及它们在预防和治疗癌症及相关疾病和症状中的应用。
• Selective NR2B Antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US20130079338A1

  公开（公告）日：2013-03-28

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，是其拮抗剂，可能对治疗中枢神经系统的各种疾病有用。
• SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS
  申请人：KUHNERT SVEN

  公开号：US20070155965A1

  公开（公告）日：2007-07-05

  Substituted bicyclic imidazo-3-yl-amine compounds are provided, as well as processes for the production thereof and pharmaceutical formulations containing these compounds. The use of these compounds for the production of pharmaceutical formulations and related methods of treatment are also provided.

  提供了替代的双环咪唑-3-基胺化合物，以及生产这些化合物的过程和含有这些化合物的药物配方。还提供了利用这些化合物生产药物配方以及相关治疗方法的用途。